Why the study?
Does MitraClip treatment improve MR severity and symptoms in Japanese patients with chronic MR at high risk for surgery?
Observational (n=30)
Yes
Does MitraClip treatment improve MR severity and symptoms in Japanese patients with chronic MR at high risk for surgery?
MitraClip treatment in a Japanese cohort of high-surgical-risk patients with chronic MR resulted in high procedural success, no major adverse events, and significant improvements in MR severity and NYHA class at 30 days.
Answers are grounded in this paper and cite their sources.
Supports short-term safety of MitraClip in high-risk Japanese MR patients; extends observational data but leaves open need for randomized confirmation.
BACKGROUND: system is a transcatheter-based therapeutic option for patients with chronic mitral regurgitation (MR) who are at high risk for surgery. A prospective, multicenter, single-arm study was initiated to confirm the transferability of this system to Japan. METHODS AND At baseline, all patients had MR 3+/4+ with 53%/47% patients with degenerative/functional etiology with mean LVEF of 50.2±12.8%, and 37% of patients were NYHA class III/IV. APS was achieved in 86.7% with no occurrence of MAE. At 30 days, 86.7% of patients had MR ≤2+ and 96.7% were NYHA class I/II. CONCLUSIONS: procedure resulted in clinically meaningful improvements in MR severity, function and quality of life measures, and low MAE rates. These early results suggest the transferability of this therapy to appropriately selected Japanese patients. (Trial Registration: clinicaltrials.gov Identifier NCT02520310.).
No takes yet. Share an insight, caveat, or question.
Hayashida et al. (2017) conducted an observational in Chronic mitral regurgitation (n=30). MitraClip was evaluated on Acute procedural success (successful implantation with MR severity ≤2+ at discharge).
Synapse has enriched 10 related papers. Consider them for comparative context: